Surface epithelial-stromal tumor explained

Surface epithelial-stromal tumor
Field:Oncology

Surface epithelial-stromal tumors are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are thought to be derived from the ovarian surface epithelium (modified peritoneum) or from ectopic endometrial or fallopian tube (tubal) tissue. Tumors of this type are also called ovarian adenocarcinoma.[1] This group of tumors accounts for 90% to 95% of all cases of ovarian cancer; however is mainly only found in postmenopausal women with the exception of the United States where 7% of cases occur in women under the age of 40.[2] [3] [4] [5] [6] [7] Serum CA-125 is often elevated but is only 50% accurate so it is not a useful tumor marker to assess the progress of treatment. 75% of women with epithelial ovarian cancer are found within the advanced-stages; however younger patients are more likely to have better prognoses than older patients.[8] [9] [10] [11] [12]

Classification

Epithelial-stromal tumors are classified on the basis of the epithelial cell type, the relative amounts of epithelium and stroma, the presence of papillary processes, and the location of the epithelial elements. Microscopic pathological features determine whether a surface epithelial-stromal tumor is benign, a borderline tumor, or malignant (evidence of malignancy and stromal invasion). Borderline tumors are of uncertain malignant potential.

This group consists of serous, mucinous, endometrioid, clear cell, and brenner (transitional cell) tumors, though there are a few mixed, undifferentiated and unclassified types.

Serous tumors

See main article: Serous tumor.

Components can include:

  1. cystic areas
  2. cystic and fibrous areas
  3. predominantly fibrous areas

The chance of malignancy of the tumor increases with the amount of solid areas present, including both papillary structures and any necrotic tissue present.

Pathology

Prognosis

The prognosis of a serous tumor, like most neoplasms, depends on

The five-year survival rate of borderline tumors and malignant tumors confined to the ovaries are 100% and 70% respectively. If the peritoneum is involved, these rates become 90% and 25%.

While the 5-year survival rates of borderline tumors are excellent, this should not be seen as evidence of cure, as recurrences can occur many years later.

Mucinous tumors

Mucinous tumors:

Pathology

Mucinous tumors are characterized by a lining of tall columnar epithelial cells with apical mucin and the absence of cilia, similar in appearance with benign cervical or intestinal epithelia. The appearance can look similar to colonic or ovarian cancer, but typically originates from the appendix (see mucinous adenocarcinoma with clinical condition Pseudomyxoma peritonei). Clear stromal invasion is used to differentiate borderline tumors from malignant tumors.

Prognosis

10-year survival rates for borderline tumors contained within the ovary, malignant tumors without invasion, and invasive malignant tumors are greater than 95%, 90%, and 66%, respectively. One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian mucinous tumors are usually unilateral (in one ovary), the presentation of bilateral mucinous tumors requires exclusion of a non-ovarian origin, usually the appendix.

Endometrioid tumors

Endometrioid tumors account for approximately 20% of all ovarian cancers and are mostly malignant (endometrioid carcinomas). They are made of tubular glands bearing a close resemblance to benign or malignant endometrium. 15-30% of endometrioid carcinomas occur in individuals with carcinoma of the endometrium, and these patients have a better prognosis. They appear similar to other surface epithelial-stromal tumors, with solid and cystic areas. 40% of these tumors are bilateral, when bilateral, metastases is often present.

Pathology

Prognosis

Prognosis again is dependent on the spread of the tumor, as well as how differentiated the tumor appears. The overall prognosis is somewhat worse than for serous or mucinous tumors, and the 5-year survival rate for patients with tumors confined to the ovary is approximately 75%.

Clear cell tumors

Clear cell tumors are characterized by large epithelial cells with abundant clear cytoplasm and may be seen in association with endometriosis or endometrioid carcinoma of the ovary, bearing a resemblance to clear cell carcinoma of the endometrium. They may be predominantly solid or cystic. If solid, the clear cells tend to be arranged in sheets or tubules. In the cystic variety, the neoplastic cells make up the cyst lining.

Prognosis

These tumors tend to be aggressive, the five year survival rate for tumors confined to the ovaries is approximately 65%. If the tumor has spread beyond the ovary at diagnosis, the prognosis is poor

Brenner tumor

Brenner tumors are uncommon surface-epithelial stromal cell tumors in which the epithelial cell (which defines these tumors) is a transitional cell. These are similar in appearance to bladder epithelia. The tumors may be very small to very large, and may be solid or cystic. Histologically, the tumor consists of nests of the aforementioned transitional cells within surrounding tissue that resembles normal ovary. Brenner tumors may be benign or malignant, depending on whether the tumor cells invade the surrounding tissue.

Small cell tumors

Small cell ovarian cancer (SCCO) are generally classified into epithelial tumors[14] associated with distinctive endocrine features.[15]

The World Health Organisation (WHO) recognises SCCO as two distinct entities: Small Cell Ovarian Cancer of Hypercalcemic Type (SCCOHT) and Small Cell Ovarian Cancer of Pulmonary Type (SCCOPT).

Small cell tumours are rare and aggressive, they contribute to less than 2% of all gynaecologic malignancies. The average age of diagnosis is 24 years old, and the majority of patients also present with hypercalcemia (62%).[16] It typically present with a unilateral large tumor. Most women die within a year of diagnosis.

Treatment

For more general information, see ovarian cancer.

Research suggests that in the first line treatment of Endometrial Ovarian Cancer (EOC), Pegylated Liposomal Doxorubicin paired with Carboplatin is a satisfactory alternative to Paclitaxel with Carboplatin.[17] In people with platinum-sensitive relapsed EOC, research has found that Pegylated Liposomal Doxorubicin with Carboplatin is a better treatment than Paclitaxel with Carboplatin.[18]

For advanced cancer of this histology, the US National Cancer Institute recommends a method of chemotherapy that combines intravenous (IV) and intraperitoneal (IP) administration.[19] Preferred chemotherapeutic agents include a platinum drug with a taxane.

Metastases

For surface epithelial-stromal tumors, the most common sites of metastasis are the pleural cavity (33%), the liver (26%), and the lungs (3%).[20]

Effect on fertility

Fertility subsequent to treatment of surface epithelial-stromal tumors depends mainly on histology and initialstaging to separate it into early borderline (or more benign) versus advanced stages of borderline (or more malignant).[21] Conservative management (without bilateral oophorectomy) of early stage borderline tumors have been estimated to result in chance of over 50% of spontaneous pregnancy with a low risk of lethal recurrence of the tumor (0.5%).[21] On the other hand, in cases of conservative treatment in advanced stage borderline tumors, spontaneous pregnancy rates have been estimated to be 35% and the risk of lethal recurrence 2%.[21]

Sources

External links

Notes and References

  1. Book: Chapter 16: Cancers of the Ovary . Kosary CL . 133–144. National Cancer Institute. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. Baguio RN, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ . NIH Pub. No. 07-6215 . Bethesda, MD . 2007 . http://seer.cancer.gov/publications/survival/surv_ovary.pdf .
  2. Centers for Disease Control and Prevention, CDC WONDER.

    United States and Puerto Rico cancer statistics, 1999–2013 inci-

    dence incidence request.Available at: http://wonder.cdc.gov/

    cancer-v2013.html. Retrieved December 1, 2016.

  3. Kashima K, Yahata T, Fujita K, Tanaka K. Outcomes of

    fertility-sparing surgery for women of reproductive age with

    FIGO stage IC epithelial ovarian cancer. Int J Gynaecol Obstet

    2013;121:53–5.

  4. Rauh-Hain JA, Foley O, Winograd D, Andrade C, Clark RM,

    Vargas RJ, et al. Clinical characteristics and outcomes of pa-

    tients with stage I epithelial ovarian cancer compared to fallo-

    pian tube cancer. Am J Obstet Gynecol 2015;212:600.e1–8.

  5. Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Gold-

    man N, et al. Fertility preservation in young women with epi-

    thelial ovarian cancer. Cancer 2009;115:4118–26.

  6. Melamed A., Rizzo A.E., Nitecki R., et al All-cause mortality after fertility-sparing surgery for stage i epithelial ovarian cancer. Obstet. Gynecol.. 2017;130(1):71-79.
  7. Book: Bradshaw . Karen D. . Schorge . John O. . Schaffer . Joseph . Lisa M. . Halvorson . Hoffman . Barbara G. . vanc . Williams' Gynecology . McGraw-Hill Professional . 2008 . 978-0-07-147257-9 .
  8. Smedley H, Sikora K. Age as a prognostic factor in epithelial

    ovarian carcinoma. Br J Obstet Gynaecol 2016;92:839–42.

  9. Ghezzi F, Cromi A, Fanfani F, Malzoni M, Ditto A, De Iaco P,

    et al. Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience. Gynecol On-

    col 2016;141:461–5.

  10. Melamed A, Keating NL, Clemmer JT, Bregar AJ, Wright JD,

    Boruta DM, et al. Laparoscopic staging for apparent stage I

    epithelial ovarian cancer. Am J Obstet Gynecol 2017;216:50.

    e1–50.e12.

  11. Kashima K, Yahata T, Fujita K, Tanaka K. Outcomes of

    fertility-sparing surgery for women of reproductive age with

    FIGO stage IC epithelial ovarian cancer. Int J Gynaecol Obstet

    2013;121:53–5.

  12. Melamed A., Rizzo A.E., Nitecki R., et al All-cause mortality after fertility-sparing surgery for stage i epithelial ovarian cancer. Obstet. Gynecol.. 2017;130(1):71-79.
  13. Book: Cotran . Ramzi S. . Kumar . Vinay . Fausto . Nelson . Robbins . Stanley L. . Abbas . Abul K. . vanc . Robbins and Cotran pathologic basis of disease . Elsevier Saunders . St. Louis, Mo . 2005 . 978-0-7216-0187-8 . 7th.
  14. http://atlasgeneticsoncology.org/Tumors/OvaryEpithTumID5230.html Atlas of Genetics and Cytogenetics in Oncology and Haematology - Ovary: Epithelial tumors
  15. Book: Small Cell and Neuroendocrine Cancers of the Ovary. Kaphan. Ariel A.. Castro. Cesar M. . vanc . 2014-01-01. John Wiley & Sons, Ltd. 9781118655344. MPH. rcela G. del Carmen MD . 139–147 . en . 10.1002/9781118655344.ch12 . FRCPATH. Robert H. Young MD. MD. John O. Schorge. MD. Michael J. Birrer.
  16. Bakhru A, Liu JR, Lagstein A . A case of small cell carcinoma of the ovary hypercalcemic variant in a teenager . Gynecologic Oncology Case Reports . 2 . 4 . 139–42 . 2012 . 24371647 . 3861231 . 10.1016/j.gynor.2012.09.001 .
  17. Lawrie TA, Rabbie R, Thoma C, Morrison J . Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer . The Cochrane Database of Systematic Reviews . 10 . CD010482 . October 2013 . 24142521 . 6457824 . 10.1002/14651858.cd010482.pub2 . John Wiley & Sons, Ltd . The Cochrane Collaboration . Lawrie TA .
  18. Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J . Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer . The Cochrane Database of Systematic Reviews . 7 . CD006910 . July 2013 . 2016 . 23835762 . 6457816 . 10.1002/14651858.cd006910.pub2 .
  19. Web site: NCI Issues Clinical Announcement for Preferred Method of Treatment for Advanced Ovarian Cancer . https://web.archive.org/web/20090113184800/http://www.cancer.gov/newscenter/pressreleases/IPchemotherapyrelease . 13 January 2009 . January 2006 . National Cancer Institute .
  20. Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME . 6 . Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence . Journal of Clinical Oncology . 20 . 4 . 982–6 . February 2002 . 11844820 . 10.1200/JCO.2002.20.4.982 .
  21. Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P . Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options . Human Reproduction Update . 19 . 2 . 151–66 . 2012 . 23242913 . 10.1093/humupd/dms047 . free .